Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: So far so good?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 2, 2016, Pages 115-

  Wattjes, Mike P ^a   Warnke, Clemens ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT;

DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; NOTE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; CHEMICALLY INDUCED; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; NATALIZUMAB;

EID: 84958953324     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311386     Document Type: Note

References (9)

1. McGuigan CCM, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87:117-25.
2. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431-41.
3. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
4. Cutter GR, Stuve O. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 2014;20:1304-5.
5. Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86: 793-8.
6. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1:755-64.
7. Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76: 792-801.
8. Sundqvist E, Buck D, Warnke C, et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014;10: e1004084.
9. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-12.